Download - Hypofractionation in breast cancer
![Page 1: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/1.jpg)
Hypofractionation in breast cancer
Dr Dodul MondalMD, DNB
All India Institute of Medical Sciences, New Delhi
Dodul Mondal
![Page 2: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/2.jpg)
Rationale
Standard radiotherapy after BCS or mastectomy for early breast cancer is 50Gy in 25 daily fractions over 5weeks (followed by 10-16Gy boost if required)
So, Why to shift to Hypofractionation??? Has to be at least equally effective for oncologic outcome
Cosmesis has to be at least equally good
Patient convenience
Can reduce burden on treatment machine
Can it serve better to provide care to more patients?
Dodul Mondal
![Page 3: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/3.jpg)
Radiobiology-Fractionation
If α ⁄β ratio of tumor is high (often 10 or greater) and α⁄β ratio of normal tissue is low (often < 5), lower dose per fraction
(hyperfractionation) is preferred
e.g., HNSCC, Ca lung
If α⁄β ratio of tumor is < normal tissue then a larger dose per fraction (hypofractionation) is preferred
e.g., prostate cancer, breast cancer
α⁄β= SENSITIVITY TO FRACTION SIZE
Dodul Mondal
![Page 4: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/4.jpg)
So, there is a chance that high dose per fraction may be an alternative,as good, if not better than conventional fractionation…
SCIENCE
BUT
EVIDENCE???
Dodul Mondal
![Page 5: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/5.jpg)
Hypofractionation in Breast cancer: Evidence
Hypo-fractionated with dose >2Gy was not popular because of fear of
increased late effect and impaired cosmesis.
Initial hypofractionation studies of 1970s failed to address adequate total dose
adjustment with high dose per fraction excessive late toxicity*
Schedules with lower total dose delivered in fewer, larger fractions were
popular in UK and Canada for several decades e.g. 40Gy/15#/3wk
Retrospective studies suggested similar outcome in terms of local control and
cosmesis.
* Bates TD, Br J Radiol. 1988 Jul;61(727):625-30.
Dodul Mondal
![Page 6: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/6.jpg)
Case Series and Cohort Studies Evaluating Hypofractionation for Whole-Breast Irradiation
Dodul Mondal
![Page 7: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/7.jpg)
Cochrane Database Syst Rev. 2008 Jul 16;(3)Dodul Mondal
![Page 8: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/8.jpg)
Local recurrence free survival
Breast appearance
Survival at five years
Late skin toxicity at five years
Late radiation toxicity in subcutaneous tissue
Unconventional fractionation regimens did not affect breast appearance or
toxicity, nor appear to affect local cancer relapse
Dodul Mondal
![Page 9: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/9.jpg)
Randomized Trials of Hypofractionation for
Whole-Breast Irradiation
Dodul Mondal
![Page 10: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/10.jpg)
Whelan et al JNCI 2002
I
N
I
T
I
A
L
R
E
S
U
L
T Dodul Mondal
![Page 11: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/11.jpg)
Cosmetic outcome and local control: Initial result
Arms Baseline 3 year 5 yearLRC AT 5
YEAR
SWBI 83%(604) 77%(498) 79%(423) 97.2%
AHBI 84%(616) 77%(518) 78%(448) 96.8%
Whelan et al JNCI 2002
Dodul Mondal
![Page 12: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/12.jpg)
Dodul Mondal
![Page 13: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/13.jpg)
Whelan et al NEJM 2010
• Median FU: 10 years
Long term follow up
Dodul Mondal
![Page 14: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/14.jpg)
Dodul Mondal
![Page 15: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/15.jpg)
Royal Marsden-GOC Trial… initial hypothesis
Dodul Mondal
![Page 16: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/16.jpg)
Royal Marsden-GOC Trial… initial hypothesis
Arm Dose (Gy) No of Fractions
Dose/fx (Gy)
Duration (weeks)
Control Arm 50 25 2 5
Test Arm1 42.9 13 3.3 5
Test Arm2 39 13 3 5
Radiotherapy and Oncology 75 (2005) 9–17
α⁄β= 3
Dodul Mondal
![Page 17: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/17.jpg)
Result- Cosmesis
Dodul Mondal
![Page 18: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/18.jpg)
Overall α⁄β= 3
Dodul Mondal
![Page 19: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/19.jpg)
UK Standardization of Breast Radiotherapy (START) trials
TrialsTotal
Dos(Gy)
No .of
Fraction
Fraction
Size (Gy)
Time
(Week)
START A 41.6 13 3.2 5
N=2235 39 13 3 5
50 25 2 5
START B40 15 2.67 3
N=2215 50 25 2 5
Dodul Mondal
![Page 20: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/20.jpg)
START A trial
Dodul Mondal
![Page 21: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/21.jpg)
Lancet Oncol 2008; 9: 331–41Dodul Mondal
![Page 22: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/22.jpg)
Local-regional tumour relapse in 2236 patientsDodul Mondal
![Page 23: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/23.jpg)
Forest plot of late normal tissue effects assessed as moderate/marked by patients and mild/marked from
photographs
Dodul Mondal
![Page 24: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/24.jpg)
LATE EFFECTS
Dodul Mondal
![Page 25: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/25.jpg)
START B trial
Dodul Mondal
![Page 26: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/26.jpg)
Dodul Mondal
![Page 27: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/27.jpg)
LOCOREGIONAL RELAPSE DISTANT RELAPSE
Dodul Mondal
![Page 28: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/28.jpg)
Survival analyses of relapse and mortality according to fractionation schedule
Dodul Mondal
![Page 29: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/29.jpg)
LATE EFFECTS
Mild/marked change in breast appearance
Dodul Mondal
![Page 30: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/30.jpg)
Forest plot of late normal tissue effects assessed as moderate/marked by patients and
mild/marked from photographs
Dodul Mondal
![Page 31: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/31.jpg)
UK FAST
trial 2003-2007
No of
patients
Total dose
(Gy)
No of
fractions
Fraction size
(Gy)
Time (week)
302 50 25 2 5
308 30 5 6 5
305 28.5 5 5.7 5
Extreme hypofractionation1: UK FAST trial
Dodul Mondal
![Page 32: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/32.jpg)
Dodul Mondal
![Page 33: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/33.jpg)
BREAST SHRINKAGE
Dodul Mondal
![Page 34: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/34.jpg)
BREAST INDURATION
Dodul Mondal
![Page 35: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/35.jpg)
Extreme hypofractionation2: UK FAST Forward trial
40.05Gy/15fx/3week
CONTROL TEST1 TEST2
27 Gy/5 fx/1week
All patients under 40 years
40-49 years with grade 3 tumours and/or LVI.
50-59 years with adverse prognostic factor,
grade or LVI
26 Gy/5 fx/1week
± Sequential Boost
10Gy/5Fx or 16Gy/8fxDodul Mondal
![Page 36: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/36.jpg)
Dodul Mondal
![Page 37: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/37.jpg)
Dodul Mondal
![Page 38: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/38.jpg)
367 women
≥70 years
Nonmetastatic T1 or T2
Breast-conserving surgery with or without lymph
node dissection followed by and adjuvant RT
50 Gy (25 fractions, 5 weeks) ± boost OR
Median follow-up 93 months
(9–140)
The 5- and 7-year CSS, LRFS,
and MFS rates were similar in
both groups
HYPOFRACTIONATION is
an acceptable alternative 32.5 Gy (five fractions of 6.5 Gy, once
weekly). No BoostDodul Mondal
![Page 39: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/39.jpg)
At this time, published data support the feasibility of hypofractionated RNI and the need
for a prospective randomized trial addressing clinical outcomes and toxicity of
hypofractionated RNI compared with standard fractionation RNIDodul Mondal
![Page 40: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/40.jpg)
Overview of hypofractionation trials
Trials Total Dos(Gy) No .of Fraction Fraction Size (Gy) Time(Week)
Ontario
COG
50 25 2 5
42.5 16 2.65 3
RMH-GOC
50 25 2 5
42.9 13 3.3 5
39 13 3 5
START A
50 25 2 5
41.6 13 3.2 5
39 13 3 5
START B50 25 2 5
40 15 2.67 3
UK FAST
TRIAL
50 25 2 5
30 5 6 5
28.5 5 5.7 5
SUMMARY OF PUBLISHED TRIALS
Dodul Mondal
![Page 41: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/41.jpg)
ONGOING…
Dodul Mondal
![Page 42: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/42.jpg)
NRG ONCOLOGY RTOG 1005
A PHASE III TRIAL OF ACCELERATED WHOLE BREAST
IRRADIATION WITH HYPOFRACTIONATION PLUS CONCURRENT
BOOST VERSUS STANDARD WHOLE BREAST IRRADIATION PLUS
SEQUENTIAL BOOST FOR EARLY-STAGE BREAST CANCER
Dodul Mondal
![Page 43: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/43.jpg)
50Gy/25fx
42.7Gy/16fx
12Gy/6fx
14Gy/7fx
25+6 or 25+7 fraction
Sequential
48Gy/15fx
40Gy/15fx
15 fractions
Concurrent
NRG ONCOLOGY RTOG 1005
Dodul Mondal
![Page 44: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/44.jpg)
NRG ONCOLOGY RTOG 1005
Dodul Mondal
![Page 45: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/45.jpg)
IMPORT LOW
Dodul Mondal
![Page 46: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/46.jpg)
IMPORT HIGH
Dodul Mondal
![Page 47: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/47.jpg)
Yat Tsang et al. Interim Analysis of Treatment Plans in the IMPORT HIGH (CR UK/06/003) Trial, 2014
Dodul Mondal
![Page 48: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/48.jpg)
Hypofractionation in early breast cancer: as goodas conventional fractionation, if not better
Similar locoregional control, survival
Cosmesis is good to excellent
Multiple RCTs, Robust data
Convenient to patients
So, more cost effective
Means to provide necessary care to more patients?
Time to change practice
Dodul Mondal
![Page 49: Hypofractionation in breast cancer](https://reader034.vdocuments.mx/reader034/viewer/2022042723/58d03f1b1a28ab8e5b8b54db/html5/thumbnails/49.jpg)
THANK YOU
Dodul Mondal